Sellon

Quick links to important sections

Sellon

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sellon

Quick Facts

Property Description
Active ingredient Selenium Sulfide
Form Topical Suspension (e.g., shampoo, lotion)
Pharmacological class Topical Antifungal and Antiseborrheic Agent
Route of administration Topical (Dermatological)
Origin Synthetic (Small Molecule)

What is Sellon and What Pharmacological Class Does it Belong To?

Sellon is a pharmaceutical preparation classified as a Topical Antifungal and Antiseborrheic Agent, strictly designed for external, localized use. The preparation's definitive pharmacological action stems from its active ingredient, Selenium Sulfide (Selenii disulfidum), a synthetic small molecule utilized specifically in dermatological care. This compound is categorized within a specialized pharmacological class because it executes a dual function: it controls fungal proliferation and simultaneously acts as a cytostatic agent by modulating the excessive production of epidermal cells. Selenium Sulfide is recognized for its ability to reduce the severity of scaling associated with seborrheic conditions. This means the medicine is clinically acknowledged for its role in controlling persistent flaking and irritation on the skin's surface.


Composition, Delivery Form, and General Purpose

Sellon is a single-ingredient product, administered topically, and is typically available as a specialized Topical Suspension, such as a lotion, shampoo, or foam. The formulation consists of the Selenium Sulfide compound suspended within an aqueous or emollient base, which is necessary to ensure the active material achieves direct and targeted contact with the affected skin surface. A distinctive feature often associated with the Sellon product line is its formulation for specific hair and sensitive skin types, sometimes including added conditioners. These common dosage forms facilitate topical administration, enabling effective application to areas like the hair-bearing scalp, which is a typical use scenario. The ultimate general benefit is the sustained control over the underlying processes—slowing down the skin’s excessive cell cycle and managing the fungal load—to promote healthy skin equilibrium.

What side effects are possible with Sellon?

Possible Side Effects and Safety Information

The official safety profile for the topical ingredient Selenium Sulfide (Sellon) is defined by its expected local effects and strict limitations on use to prevent systemic exposure. All adverse reactions and safety statements are sourced from government regulatory documents.


Adverse Reaction Scope

Adverse effects are primarily classified as Skin and subcutaneous tissue disorders, occurring at the application site. Common, expected side effects documented in regulatory labeling include local skin irritation, dryness or oiliness of the hair and scalp, temporary hair loss, and discoloration of the hair (which can be minimized by thorough rinsing).

Serious adverse reactions include the potential for severe hypersensitivity reactions, such as generalized allergic responses. Furthermore, official warnings emphasize the risk of systemic toxicity (which may involve neurological or gastrointestinal effects) if the product is accidentally ingested or used on compromised skin.


Safety Constraints and Considerations

The preparation is contraindicated in persons with a known hypersensitivity to any of its components. The most critical safety restrictions stated in the labeling are:

  • The product is strictly for external use only.
  • It must not be used on broken skin or acutely inflamed areas, as this increases the risk of unwanted systemic absorption.
  • Contact with the eyes and other mucous membranes must be avoided.

Regarding specific populations, the product is classified by the FDA as Pregnancy Category C for certain uses, and its safety has not been established in infants and young children. It is also not known if the drug is secreted in human milk during breastfeeding, meaning caution is advised in these situations.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory information concerning overdose for Sellon (Selenium Sulfide topical suspension) focuses specifically on the risk associated with Accidental Oral Ingestion of the product, as documented in the official prescribing information.


Overdose Scope and Risk Assessment

Feature Official Regulatory Statement
Documented Manifestations Official labeling reports no documented cases of serious toxicity in humans resulting from acute ingestion of the topical preparation.
Potential Outcomes Acute toxicity studies indicate that swallowing large amounts could result in potential human toxicity, necessitating emergency awareness.
Exposure Circumstance The primary overdose risk addressed is the Accidental Oral Ingestion of the topical suspension, not misuse of the topical application itself.
Population Consideration A mandatory caution instructs users to KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN to mitigate the risk of accidental exposure.

Emergency Response and Management

Feature Official Regulatory Statement
Mandatory Action In case of accidental overdose, individuals must immediately seek professional assistance or contact a Poison Control Center.
Supportive Measures Evacuation of the stomach contents should be considered as a supportive procedure for acute oral ingestion.
Antidote Status The official prescribing information states that no specific antidote is documented or known for this medication.

The regulatory profile requires immediate medical attention upon accidental oral exposure due to the potential for systemic toxicity, even in the absence of documented human serious toxicity reports from acute ingestion. This stance mandates urgent consultation with a Poison Control Center or other medical professional for evaluation and consideration of supportive measures.

Therapeutic Uses of Sellon

What Sellon Treats: Main Uses and Benefits


The topical use of this preparation is applied across domains where additional symptomatic support is needed for chronic skin conditions. It is commonly used to help manage the recurring manifestations of dandruff, seborrheic dermatitis, and the localized fungal infection Tinea Versicolor.

The medication is relevant for easing symptoms related to itching, flaking, and scaling that often accompany these disorders. For patients, this provides symptomatic relief that may contribute to improved day-to-day comfort during periods of heightened symptoms. The preparation plays a role in managing symptoms that create noticeable interference with functional stability, which can be summarized simply:

“It is considered relevant for supporting patients during difficult episodes by easing distress.”


Quick Fact: Relief for Persistent Discomfort Symptom Type Condition Category Primary Benefit
Excessive Flaking & Itching Recurrent or Episodic Manifestations Contributes to easing the overall symptom load

Regulatory References

  1. official overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Sellon — official regulatory information

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults and Children (generally ge 2 years of age) for the approved indications.
Populations for whom use is not recommended Pregnant women (for Tinea Versicolor) under ordinary circumstances. Children under 5 years (specific regional labeling).
Populations for whom use is contraindicated Patients with known hypersensitivity to selenium sulfide or any component of the formulation.
Age-related eligibility rules Infants (children younger than 2 years of age): Safety and effectiveness have not been established. Older Adults: No different problems are expected compared to younger adults.
Pregnancy and lactation eligibility status Pregnancy: Classified as Category C by the FDA. Lactation: Use with caution; application around the breast should be avoided.
Eligibility-related restrictions Do not use on broken skin, inflamed areas, or when acute inflammation or exudation (oozing) is present, due to potential increased absorption.

Eligibility Classifications (High-Level)

Classification Regulatory Statement / Basis
Eligibility severity classification Contraindicated (Hypersensitivity, Broken Skin), Use with Caution (Lactation), Not Established (Infants <2 years).
Eligibility-context constraints The primary constraint is topical application to intact skin, prohibiting use on skin with compromised integrity.

Connection to the overall eligibility profile

Official regulatory documents define Sellon's eligibility profile by establishing absolute contraindications based on ingredient allergy and the presence of compromised skin integrity. The profile sets forth specific limitations by classifying use as not established for infants and imposing conditional restrictions for use during pregnancy and lactation, ensuring the criteria for use are strictly defined by regulatory standards.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Sellon (Selenium Sulfide Topical) highlights a highly localized interaction profile, primarily due to minimal systemic absorption through intact skin. Consequently, no significant systemic drug-drug interactions affecting metabolic enzymes (such as CYP450) or drug transporters are documented in the prescribing information.


Condition and Chemical Constraints

The established restrictions relate to local physical effects and the condition of the application site.

Constraint Type Official Regulatory Finding
Condition-Dependent Exposure Risk Use on inflamed, damaged, or broken skin may act as a condition that leads to increased systemic exposure of the active ingredient, raising the potential for systemic effects.
Chemical Co-Administration Restriction Contact with cosmetic hair treatments, such as bleaching, tinting, or perms, can result in a physical interaction causing hair discoloration if the product is not thoroughly rinsed off.

Documented Systemic Interaction Status

Conventional systemic interactions with other medicines, food, alcohol, or herbal products are not documented in the official regulatory labeling for this topical product. The only formal contraindication listed is a known hypersensitivity to Selenium Sulfide or any component of the formulation. The product’s interaction profile is thus structurally defined by mandatory physical separation requirements and the integrity of the skin barrier at the application site.

Mechanism of Action

The action of Sellon, derived from its active ingredient Selenium Sulfide, is based on two complementary mechanistic domains: a cytostatic effect on epidermal cells and a fungicidal effect on surface microorganisms.

Modulation of Epidermal Cell Turnover

This domain covers the drug's cytostatic action, which involves an antimitotic effect targeted at the basal layer of epidermal cells. The molecule interferes with the cellular machinery necessary for reproduction, leading to a molecular blockade that reduces the mitotic rate and slows the pathological acceleration of skin cell renewal. This mechanistic cascade results in the normalization of skin shedding and reduction of excessive corneocyte production.

Targeted Disruption of Fungal Metabolism

This domain addresses the drug's role as a fungicidal agent against yeasts, specifically Malassezia species, a surface-dwelling organism. The mechanism involves the disruption of fungal cellular metabolism by generating Reactive Oxygen Species (ROS) within the yeast cells. This action suppresses fungal proliferation and viability, resulting in reduced local microbial load and the subsequent reduction in the release of irritating microbial metabolites.

Dosage and Administration Information

Sellon is a topical preparation administered exclusively to the skin or scalp. Its use follows specific, structured regimens. The preparation, typically a suspension or shampoo, must be shaken well before use to ensure the active compound is uniformly distributed. The dosage and frequency pattern depend on the condition being addressed.

For conditions of the scalp like seborrheic dermatitis or dandruff, the initial course involves applying approximately 1 to 2 teaspoonfuls of the 2.5% suspension. This is applied twice weekly for two weeks to establish initial control. Following this, the application frequency is reduced to intermittent use, such as once every one to four weeks, based only on the need to maintain the initial outcome.

When used for localized fungal infections such as Tinea Versicolor, the regimen is shorter and more definite. The medicine is applied once a day for a course lasting seven days. Regardless of the indication, specific contact times must be observed: the product remains on the scalp for 2 to 3 minutes or on the body for 10 minutes before a thorough rinsing is performed.

Official usage instructions also include important procedural conditions: jewelry must be removed prior to application, as the suspension may cause discoloration. Furthermore, chemically treated hair requires rinsing with cool water for at least five minutes after use. For younger populations, the safety and effectiveness of the product have not been established in infants under two years of age.

Recent Clinical Evidence

This section provides an objective overview of the clinical research and study structures related to topical selenium sulfide (Sellon), focusing on what official sources and peer-reviewed trials have examined and what has been observed so far, without offering any clinical guidance or recommendations. The text uses language designed to reflect the scientific uncertainty and limitations inherent in medical research.


Evidence for Use in Dandruff (Pityriasis Capitis)

Research exploring the condition of dandruff has primarily used short-term Randomized Controlled Trials (RCTs) in adult populations experiencing periods of heightened symptom activity. Researchers monitored how symptoms evolved by measuring outcomes related to physical discomfort, specifically tracking changes in scaling and the intensity of associated itching, or pruritus. Studies reported patterns of change in measured total scale scores from baseline over the typical four-week treatment period, and some trials noted monitored changes in the count of the Malassezia fungus, which is monitored in research settings.


Evidence for Use in Seborrheic Dermatitis and Tinea Versicolor

For seborrheic dermatitis, the research base also relies on short-term, comparative RCTs evaluating outcomes linked to inflammatory or irritative states, such as investigator-rated severity scores for redness and scaling. For tinea versicolor, studies focused on mycological outcomes, defined as the elimination of the Malassezia fungus confirmed by lab tests, and the clinical resolution of the characteristic skin patches. Findings indicate that data show patterns related to how the lesions evolve following the study intervention, but recurrence rates were commonly observed, indicating a pattern of symptom return over time.


Research Gaps and Long-Term Uncertainty

The majority of high-quality RCTs for Sellon focus on the short-term, acute treatment phase. Since these conditions are characterized by fluctuating manifestations, a key research limitation is that the long-term patterns and durability of the initial response are not fully established by the primary research trials alone. Data are still emerging regarding the optimal schedule for intermittent use to address the common pattern of recurrence. Furthermore, evidence for children and older adults is limited, meaning the existing research describes group patterns and does not determine whether an individual outside those study populations will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Sellon (FAQ)


Q: How quickly does Sellon usually start to work?

Official information provides the typical timeframe for initial symptom control, rather than a specific onset time. For scalp conditions, the initial course is generally described as two applications per week for two weeks. For tinea versicolor, the course involves once-daily use for seven days, which is the time frame for achieving initial control.


Q: Do the side effects of Sellon usually go away?

Common and mild adverse effects that occur at the application site, such as local irritation or dryness, are generally described in safety summaries as transient and self-limiting. This indicates that they are expected to resolve without specific intervention. Official guidance indicates that use should be discontinued if side effects persist or are severe.


Q: Is it true that Sellon can cause [Specific Common Symptom]?

Official labeling documents that application may cause local side effects, including skin irritation, dryness or oiliness of the hair/scalp, and temporary hair loss. It can also cause temporary hair discoloration, which is minimized by thoroughly rinsing the product. These effects are expected local reactions to the topical application.


Q: Are there any food or drinks that should be avoided while taking Sellon?

Because Sellon is a topical preparation strictly for external use on the skin, minimal systemic absorption is expected. Official drug documents state that no systemic interactions with food, drink, or alcohol are documented.


Q: What is the official classification or category of Sellon?

Sellon is classified as a topical antifungal and antiseborrheic agent. This classification reflects the drug’s dual function in controlling fungal growth on the skin’s surface and normalizing the excessive turnover of skin cells (anti-seborrheic effect).


Q: Is Sellon safe to use during pregnancy?

The product is classified by the FDA as Pregnancy Category C for certain uses. This category indicates that animal reproduction studies have shown an adverse effect on the fetus, but there are no adequate and well-controlled studies in humans. The manufacturer's labeling for some products describes circumstances where caution is advised or use is not recommended.


Q: Is Sellon safe to use while breastfeeding?

Official information states that it is not known whether the topical ingredient is secreted in human milk. Regulatory documents note that use is with caution, and that application of the product around the breast area is noted as an area to avoid.


Q: What research is currently being done on Sellon?

Research documents identify several knowledge gaps in the available clinical data. These gaps, which suggest areas of ongoing study, include the optimal long-term maintenance schedule for intermittent use and obtaining more extensive data for older adults and children under the age of five.


Q: Do you need to gradually stop taking Sellon?

The recommended regimen for scalp conditions involves a gradual reduction in frequency rather than an abrupt stop. After the initial treatment phase, use is reduced to intermittent application (e.g., weekly or every few weeks) only as frequently as needed to maintain symptom control.


Q: Is Sellon considered a habit-forming or controlled substance?

No. Official drug labeling specifies that this product is not classified as a controlled substance by the DEA (Drug Enforcement Administration), which is the regulatory designation for products that do not have a recognized potential for abuse.


Q: Why might a person need to stop taking Sellon?

Official patient information states that use is to be discontinued if sensitivity reactions occur, such as severe irritation or generalized allergic responses. Patients are also advised to stop use if the treated condition worsens or does not show improvement after the recommended course of regular use.


Q: What should be done if a potential interaction with another drug is found?

Patients are instructed in official guidance to inform their healthcare professional about all prescription and nonprescription (over-the-counter) medicines, supplements, and products they are using. The purpose of this is to discuss potential risks and necessary precautions.


Q: Why is my prescription for Sellon a different dosage strength than what my friend takes?

Official guidance states that the dosage can be different for different patients. The precise strength and application schedule are determined by the healthcare provider based on the specific medical problem being treated and the individual patient's needs.


Q: What is the maximum recommended duration of Sellon treatment?

The initial acute treatment duration is strictly defined: for the acute treatment of tinea versicolor, the course is typically seven days. For long-term scalp conditions, there is no fixed maximum duration; rather, the product is used intermittently only as frequently as needed to maintain symptom control.


Q: Is it possible for Sellon to stop working over time?

Research reports do not typically describe the drug 'stopping work.' However, studies indicate that recurrence rates are commonly observed for the conditions treated, suggesting a pattern of symptom return over time, which necessitates intermittent use to maintain control.


Q: How long does Sellon stay in the body after the last dose?

Due to the product being for topical use on intact skin, minimal systemic absorption is documented. Studies reported no detectable increases in blood or urine levels of the active ingredient under typical use conditions, underscoring the negligible amount that enters the body.

How should Sellon be stored and disposed of?

How to Store and Dispose of Sellon?

Official instructions for storing and discarding Sellon (Selenium Sulfide Topical Suspension) are mandated by regulatory agencies to ensure product stability and safety.

Official Storage Requirements

Storage Condition Requirement
Temperature Store at Controlled Room Temperature (typically 20 C to 25 C), and keep from freezing.
Container Rules Keep the medicine in its original, tightly closed container; store away from excessive heat and direct light.
Child Safety Keep out of the reach of children and pets.

Official Disposal Instructions

Disposal must adhere to all local and national regulations. The active ingredient, Selenium Sulfide, is classified by regulatory authorities as a hazardous waste in its commercial form (e.g., U.S. EPA RCRA Code U205).

Therefore, do not discard unused or expired product by flushing it down a toilet or pouring it into any drain or sewer system. Disposal must follow official hazardous waste guidelines to avoid release to the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sellon found in:

A-Z Index: